The ALDH1B1 Knockout MCF-7 Polyclonal Cells product provides a heterogeneous CRISPR/Cas9-edited cell population derived from the MCF-7 breast adenocarcinoma line, generated for loss-of-function analysis of the ALDH1B1 gene. This polyclonal knockout pool harbors a diverse array of gene disruptions introduced by CRISPR/Cas9-mediated targeting, mimicking the genetic variability inherent in tumor cell populations. By abrogating ALDH1B1 protein production, this model facilitates robust gene function studies without the constraints of clonal selection.
MCF-7 cells are a well-characterized model of estrogen receptor-positive (ER+) breast adenocarcinoma, originally established from a metastatic pleural effusion. These adherent, epithelial-like cells retain hormone responsiveness and are widely employed to investigate ER signaling, endocrine resistance, and tumor progression mechanisms. Their stable genotype and ease of genetic manipulation make them an optimal host for CRISPR-engineered knockout models. Disruption of ALDH1B1 within this context enables dissection of aldehyde dehydrogenase contributions to breast cancer biology in a clinically relevant setting.
ALDH1B1 is a mitochondrial aldehyde dehydrogenase that oxidizes acetaldehyde and retinaldehyde, contributing to detoxification and retinoic acid synthesis. Its expression is driven by Wnt/??-catenin signaling via TCF/LEF transcription factors and can be modulated by PPAR?? and HNF4??. ALDH1B1-produced retinoic acid activates RAR/RXR complexes, regulating genes involved in oxidative stress responses and differentiation. The enzyme interacts with ALDH1A1 and participates in the retinaldehyde metabolic network alongside CYP26 enzymes. Through retinoic acid production, ALDH1B1 links aldehyde metabolism to transcriptional regulation of stemness and stress resistance pathways.
In MCF-7 cells, ALDH1B1 sustains a cancer stem cell phenotype characterized by high ALDH activity and CD44+/CD24? expression, while also providing protection against chemotherapeutics and oxidative stress. Retinoic acid generated by ALDH1B1 influences differentiation and apoptosis, impacting tumorigenic capacity. This polyclonal knockout model allows direct examination of ALDH1B1-dependent effects on ALDH activity, tumorsphere formation, retinoic acid signaling, and drug sensitivity. The heterogeneous knockout population accurately reflects tumor cell diversity, enhancing the physiological relevance of functional analyses.
Researchers can utilize this polyclonal knockout product to study ALDH1B1 in breast cancer stem cell biology, aldehyde detoxification, and retinoic acid signaling. Compatible assays include Aldefluor activity measurements, CD44/CD24 flow cytometry, tumorsphere formation, Western blotting, RT-qPCR, retinoic acid luciferase reporter assays, and colony formation or apoptosis assays. This model supports pooled loss-of-function screens and studies requiring population-level heterogeneity. For additional details, please contact Ascent Research.
